Pelthos Therapeutics

Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026

Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will…

Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the…

Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes

DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™…

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and…

Pelthos Therapeutics Announces First Quarter 2026 Financial Results

ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units…

Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026

Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will…